+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CAR-T Cell Therapy Market, By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Others), By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition Forecast & Opportunities, 2026

  • ID: 5410182
  • Report
  • August 2021
  • Region: Global
  • 115 Pages
  • TechSci Research
UP TO OFF
until Dec 31st 2021
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Car-T Cell Therapy Market is Expected to Reach USD 6134.56 Million by 2026, Growing at a CAGR of 33.11% Over the Forecast Period.

FEATURED COMPANIES

  • AbbVie Inc.
  • Autolus Therapeutics PLC
  • Cellectis SA
  • Humanigen Inc
  • Merck & Co. Inc.
  • Pfizer Inc.
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global CAR-T Cell Therapy Market is expected to reach USD6134.56 million by 2026, growing at a CAGR of 33.11% over the forecast period. The growth in the market can be attributed to increasing prevalence of cancer and growing pool of patients who are showing response failure towards alternative treatments. Rising clinical trials and development of new and effective therapy options is also acting as key growth driver for the Global CAR-T Cell Therapy Market. In addition to this, growing need for breakthrough therapeutic solutions and effectiveness of CAR-T cell therapy in treating cancer are expected to fuel the market growth through 2026.

Moreover, thriving immuno-oncology sector and increasing R&D expenditure are expected to positively influence the growth of the Global CAR-T Cell Therapy market. However, the Global CAR-T Cell Therapy market might also face some challenges. The side effects of CAR-T cell therapy may lead to neurological problems and cytokine release syndrome (CRS), which might hamper the market growth. Also, the complicated manufacturing process of CAR-T cells makes it a costly treatment.

The Global CAR-T Cell Therapy Market can be segmented based on product type, tumor type, indication, treatment type, targeted antigen, end-user, company and region. Based on indication, the market can be segmented into Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle cell lymphoma (MCL) and others. Among them, Acute Lymphoblastic Leukemia (ALL) segment is expected to witness the fastest CAGR during the forecast period owing to its high prevalence around the globe.

Regionally, North America dominated the Global CAR-T Cell Therapy Market in 2020 and is further expected to hold its dominance during the forecast period owing to increasing development and launch of new therapies for the treatment of cancer by key healthcare and drug manufacturers in the region. Further, Europe is expected to be the second largest market for global CAR-T cell therapy through 2026 as the region is witnessing extensive research for development of cancer treatment therapies.

Major companies operating in the Global CAR-T Cell Therapy Market include Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Co., Cellectis SA, Amgen Inc., Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc., Novartis AG, Poseida Therapeutics Inc., Johnson & Johnson SA, Allogene Therapeutics Inc., Autolus Therapeutics PLC, Humanigen Inc., Sangamo Therapeutics, Inc., among others. The market players are investing on extensive research & development activities to launch new CAR-T Cell therapies to strengthen their positions in global market.

Years considered for this report:

  • Historical Years: 2017-2019
  • Base Year: 2020
  • Estimated Year: 2021E
  • Forecast Period: 2022F-2026F

Objective of the Study:

  • To analyze the historical growth in the market size of the Global CAR-T Cell Therapy Market from 2017 to 2020.
  • To estimate and forecast the market size of the Global CAR-T Cell Therapy Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global CAR-T Cell Therapy Market based on product type, tumor type, indication, treatment type, by targeted antigen, by end-user, company and regional distribution.
  • To identify drivers and challenges for the Global CAR-T Cell Therapy Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in the Global CAR-T Cell Therapy Market.
  • To identify and analyze the profile of leading players operating in the Global CAR-T Cell Therapy Market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of CAR-T cell therapy companies across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.

The publisher calculated the Global CAR-T Cell Therapy Market size by using a bottom-up approach, where data for various end-user industries and its application across various product types were recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.

Key Target Audience:

  • CAR-T cell therapy drug manufacturers/ companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as CAR-T cell therapy drug manufacturing companies, end-users etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the Global CAR-T Cell Therapy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global CAR-T Cell Therapy Market, By Product Type:

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Abecma (idecabtagene vicleucel)
  • Others
  • Global CAR-T Cell Therapy Market, By Tumor Type
  • Hematological Malignancies
  • Solid Tumors

Global CAR-T Cell Therapy Market, By Indication:

  • Diffused Large B-cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Others
  • Global CAR-T Cell Therapy Market, By Treatment Type
  • Single Treatment
  • Combination Treatment

Global CAR-T Cell Therapy Market, By Targeted Antigen:

  • CD 19
  • BCMA (B-Cell Maturation Antigen)
  • Others

Global CAR-T Cell Therapy Market, By End-User:

  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Others

Global CAR-T Cell Therapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global CAR-T Cell Therapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.

Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Autolus Therapeutics PLC
  • Cellectis SA
  • Humanigen Inc
  • Merck & Co. Inc.
  • Pfizer Inc.
1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global CAR-T Cell Therapy Market

4. Executive Summary

5. Voice of Customer
5.1. Brand Awareness
5.2. Unmet Need and Challenges
5.3. Factors Driving the CAR-T Cell Therapy Market

6. Global CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others)
6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
6.2.3. By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.7. By Company (2020)
6.2.8. By Region
6.3. Product Market Map

7. North America CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tumor Type
7.2.2. By Indication
7.2.3. By Treatment Type
7.2.4. By Targeted Antigen
7.2.5. By End User
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States CAR-T Cell Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tumor Type
7.3.1.2.2. By Indication
7.3.1.2.3. By Treatment Type
7.3.1.2.4. By Targeted Antigen
7.3.1.2.5. By End User
7.3.2. Canada CAR-T Cell Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tumor Type
7.3.2.2.2. By Indication
7.3.2.2.3. By Treatment Type
7.3.2.2.4. By Targeted Antigen
7.3.2.2.5. By End User
7.3.3. Mexico CAR-T Cell Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tumor Type
7.3.3.2.2. By Indication
7.3.3.2.3. By Treatment Type
7.3.3.2.4. By Targeted Antigen
7.3.3.2.5. By End User

8. Europe CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tumor Type
8.2.2. By Indication
8.2.3. By Treatment Type
8.2.4. By Targeted Antigen
8.2.5. By End User
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. Germany CAR-T Cell Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tumor Type
8.3.1.2.2. By Indication
8.3.1.2.3. By Treatment Type
8.3.1.2.4. By Targeted Antigen
8.3.1.2.5. By End User
8.3.2. France CAR-T Cell Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tumor Type
8.3.2.2.2. By Indication
8.3.2.2.3. By Treatment Type
8.3.2.2.4. By Targeted Antigen
8.3.2.2.5. By End User
8.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tumor Type
8.3.3.2.2. By Indication
8.3.3.2.3. By Treatment Type
8.3.3.2.4. By Targeted Antigen
8.3.3.2.5. By End User
8.3.4. Italy CAR-T Cell Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Tumor Type
8.3.4.2.2. By Indication
8.3.4.2.3. By Treatment Type
8.3.4.2.4. By Targeted Antigen
8.3.4.2.5. By End User
8.3.5. Spain CAR-T Cell Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Tumor Type
8.3.5.2.2. By Indication
8.3.5.2.3. By Treatment Type
8.3.5.2.4. By Targeted Antigen
8.3.5.2.5. By End User

9. Asia-Pacific CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tumor Type
9.2.2. By Indication
9.2.3. By Treatment Type
9.2.4. By Targeted Antigen
9.2.5. By End User
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. Japan CAR-T Cell Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tumor Type
9.3.1.2.2. By Indication
9.3.1.2.3. By Treatment Type
9.3.1.2.4. By Targeted Antigen
9.3.1.2.5. By End User
9.3.2. China CAR-T Cell Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tumor Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Treatment Type
9.3.2.2.4. By Targeted Antigen
9.3.2.2.5. By End User
9.3.3. India CAR-T Cell Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tumor Type
9.3.3.2.2. By Indication
9.3.3.2.3. By Treatment Type
9.3.3.2.4. By Targeted Antigen
9.3.3.2.5. By End User
9.3.4. South Korea CAR-T Cell Therapy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Tumor Type
9.3.4.2.2. By Indication
9.3.4.2.3. By Treatment Type
9.3.4.2.4. By Targeted Antigen
9.3.4.2.5. By End User
9.3.5. Australia CAR-T Cell Therapy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Tumor Type
9.3.5.2.2. By Indication
9.3.5.2.3. By Treatment Type
9.3.5.2.4. By Targeted Antigen
9.3.5.2.5. By End User

10. South America CAR-T Cell Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tumor Type
10.2.2. By Indication
10.2.3. By Treatment Type
10.2.4. By Targeted Antigen
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil CAR-T Cell Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tumor Type
10.3.1.2.2. By Indication
10.3.1.2.3. By Treatment Type
10.3.1.2.4. By Targeted Antigen
10.3.1.2.5. By End User
10.3.2. Argentina CAR-T Cell Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tumor Type
10.3.2.2.2. By Indication
10.3.2.2.3. By Treatment Type
10.3.2.2.4. By Targeted Antigen
10.3.2.2.5. By End User
10.3.3. Colombia CAR-T Cell Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tumor Type
10.3.3.2.2. By Indication
10.3.3.2.3. By Treatment Type
10.3.3.2.4. By Targeted Antigen
10.3.3.2.5. By End User

11. Middle East and Africa CAR-T Cell Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Tumor Type
11.2.2. By Indication
11.2.3. By Treatment Type
11.2.4. By Targeted Antigen
11.2.5. By End User
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa CAR-T Cell Therapy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Tumor Type
11.3.1.2.2. By Indication
11.3.1.2.3. By Treatment Type
11.3.1.2.4. By Targeted Antigen
11.3.1.2.5. By End User
11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Tumor Type
11.3.2.2.2. By Indication
11.3.2.2.3. By Treatment Type
11.3.2.2.4. By Targeted Antigen
11.3.2.2.5. By End User
11.3.3. UAE CAR-T Cell Therapy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Tumor Type
11.3.3.2.2. By Indication
11.3.3.2.3. By Treatment Type
11.3.3.2.4. By Targeted Antigen
11.3.3.2.5. By End User

12. Market Dynamics
12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape
14.1. Competition Outlook
14.2. Players Profiled (Leading Companies)
14.2.1. Gilead Sciences Inc.
14.2.2. AbbVie Inc.
14.2.3. Bristol Myers Squibb Co.
14.2.4. Cellectis SA
14.2.5. Amgen Inc.
14.2.6. Pfizer Inc.
14.2.7. Merck & Co. Inc.
14.2.8. Intellia Therapeutics Inc.
14.2.9. Novartis AG
14.2.10. Poseida Therapeutics Inc.
14.2.11. Johnson & Johnson SA
14.2.12. Allogene Therapeutics Inc.
14.2.13. Autolus Therapeutics PLC
14.2.14. Humanigen Inc
14.2.15. Sangamo Therapeutics, Inc.

15. Strategic Recommendations

16. About the Publisher & Disclaimer

List of Figures
Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, , 2017-2026F
Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 8: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2020
Figure 9: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2026F
Figure 10: Global CAR-T Cell Therapy Product Market Map, By Value, 2017-2026F
Figure 11: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 12: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 13: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 14: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 15: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 16: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 17: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
Figure 18: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 19: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 20: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 21: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 22: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 23: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 24: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 25: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 26: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 27: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 28: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 29: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 30: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 31: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 32: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 33: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 34: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 35: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 36: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 37: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 38: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 39: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 40: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 41: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 42: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
Figure 43: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 44: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 45: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 46: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 47: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 48: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 49: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 50: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 51: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 52: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 53: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 54: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 55: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 56: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 57: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 58: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 59: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 60: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 61: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 62: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 63: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 64: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 65: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 66: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 67: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 68: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 69: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 70: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 71: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 72: Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 73: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 74: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 75: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 76: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 77: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 78: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 79: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
Figure 80: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 81: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 82: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 83: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 84: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 85: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 86: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 87: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 88: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 89: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 90: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 91: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 92: India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 93: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 94: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 95: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 96: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 97: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 98: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 99: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 100: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 101: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 102: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 103: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 104: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 105: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 106: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 107: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 108: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 109: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 110: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 111: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 112: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 113: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 114: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 115: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 116: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
Figure 117: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 118: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 119: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 120: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 121: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 122: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 123: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 124: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 125: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 126: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 127: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 128: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 129: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 130: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 131: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 132: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 133: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 134: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 135: Middle East and Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 136: Middle East and Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 137: Middle East and Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 138: Middle East and Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 139: Middle East and Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 140: Middle East and Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 141: Middle East and Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
Figure 142: South Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 143: South Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 144: South Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 145: South Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 146: South Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 147: South Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 148: Saudi Arabia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 149: Saudi Arabia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 150: Saudi Arabia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 151: Saudi Arabia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 152: Saudi Arabia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 153: Saudi Arabia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Figure 154: UAE CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
Figure 155: UAE CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
Figure 156: UAE CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
Figure 157: UAE CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
Figure 158: UAE CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
Figure 159: UAE CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Gilead Sciences Inc.
  • AbbVie Inc.
  • Bristol Myers Squibb Co.
  • Cellectis SA
  • Amgen Inc.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Intellia Therapeutics Inc.
  • Novartis AG
  • Poseida Therapeutics Inc.
  • Johnson & Johnson SA
  • Allogene Therapeutics Inc.
  • Autolus Therapeutics PLC
  • Humanigen Inc
  • Sangamo Therapeutics, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll